These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 20952508)

  • 21. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas.
    Hecht M; Papoutsi M; Tran HD; Wilting J; Schweigerer L
    Cancer Res; 2004 Sep; 64(17):6109-18. PubMed ID: 15342394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway.
    Hu B; Guo P; Bar-Joseph I; Imanishi Y; Jarzynka MJ; Bogler O; Mikkelsen T; Hirose T; Nishikawa R; Cheng SY
    Oncogene; 2007 Aug; 26(38):5577-86. PubMed ID: 17369861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors.
    Mira A; Morello V; Céspedes MV; Perera T; Comoglio PM; Mangues R; Michieli P
    Oncotarget; 2017 Jun; 8(24):38193-38213. PubMed ID: 28445144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.
    Schueneman AJ; Himmelfarb E; Geng L; Tan J; Donnelly E; Mendel D; McMahon G; Hallahan DE
    Cancer Res; 2003 Jul; 63(14):4009-16. PubMed ID: 12873999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities.
    Hong SW; Jung KH; Lee HS; Son MK; Yan HH; Kang NS; Lee J; Hong SS
    Carcinogenesis; 2013 Sep; 34(9):2156-69. PubMed ID: 23671132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
    Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.
    Jahangiri A; De Lay M; Miller LM; Carbonell WS; Hu YL; Lu K; Tom MW; Paquette J; Tokuyasu TA; Tsao S; Marshall R; Perry A; Bjorgan KM; Chaumeil MM; Ronen SM; Bergers G; Aghi MK
    Clin Cancer Res; 2013 Apr; 19(7):1773-83. PubMed ID: 23307858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis.
    Abounader R; Laterra J
    Neuro Oncol; 2005 Oct; 7(4):436-51. PubMed ID: 16212809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The hepatocyte growth factor antagonist NK4 inhibits indoleamine-2,3-dioxygenase expression via the c-Met-phosphatidylinositol 3-kinase-AKT signaling pathway.
    Wang D; Saga Y; Sato N; Nakamura T; Takikawa O; Mizukami H; Matsubara S; Fujiwara H
    Int J Oncol; 2016 Jun; 48(6):2303-9. PubMed ID: 27082119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis.
    Abounader R; Lal B; Luddy C; Koe G; Davidson B; Rosen EM; Laterra J
    FASEB J; 2002 Jan; 16(1):108-10. PubMed ID: 11729097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular and molecular mechanisms of HGF/Met in the cardiovascular system.
    Gallo S; Sala V; Gatti S; Crepaldi T
    Clin Sci (Lond); 2015 Dec; 129(12):1173-93. PubMed ID: 26561593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
    Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HGF-MET cascade, a key target for inhibiting cancer metastasis: the impact of NK4 discovery on cancer biology and therapeutics.
    Mizuno S; Nakamura T
    Int J Mol Sci; 2013 Jan; 14(1):888-919. PubMed ID: 23296269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
    Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
    Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway.
    Yang X; Zhang XF; Lu X; Jia HL; Liang L; Dong QZ; Ye QH; Qin LX
    Hepatology; 2014 May; 59(5):1874-85. PubMed ID: 24259426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interruption of the HGF paracrine loop by NK4, an HGF antagonist, reduces VEGF expression of CT26 cells.
    Kubota T; Matsumura A; Taiyoh H; Izumiya Y; Fujiwara H; Okamoto K; Ichikawa D; Shiozaki A; Komatsu S; Nakanishi M; Kuriu Y; Murayama Y; Ikoma H; Ochiai T; Nakamura T; Matsumoto K; Nakamura T; Otsuji E
    Oncol Rep; 2013 Aug; 30(2):567-72. PubMed ID: 23722408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
    Yu Y; Chen Y; Ding G; Wang M; Wu H; Xu L; Rui X; Zhang Z
    Biochem Biophys Res Commun; 2015 Aug; 464(1):154-60. PubMed ID: 26093299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.
    Hatipoglu G; Hock SW; Weiss R; Fan Z; Sehm T; Ghoochani A; Buchfelder M; Savaskan NE; Eyüpoglu IY
    Cancer Sci; 2015 Feb; 106(2):160-70. PubMed ID: 25458015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.